Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes

2005 ◽  
Vol 83 (1) ◽  
pp. 98-103 ◽  
Author(s):  
Shamir R Mehta ◽  
John W Eikelboom ◽  
Catherine Demers ◽  
Aldo P Maggioni ◽  
Patrick J Commerford ◽  
...  

There are limited data regarding the incidence and clinical significance of congestive heart failure (CHF) in patients with non-ST segment elevation acute coronary syndromes (ACS). The objectives of this study were to examine the incidence, predictors, and clinical outcomes in patients with ACS without ST elevation who develop CHF. We studied patients with unstable angina or non-ST segment elevation myocardial infarction (NSTEMI) randomized to hirudin or unfractionated heparin in the Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) trial. The diagnosis of CHF was based on a combination of clinical and radiographic features. Patients were followed for 6 months. Of 10 141 randomized patients, 501 (4.9%) developed CHF within the first week and 643 (6.3%) during 6 months of followup. Independent predictors for the development of CHF were older age, female sex, diabetes, prior MI, prior CHF, and NSTEMI at presentation. Compared with patients who did not develop CHF, patients who developed CHF were at increased risk of death (odds ratio (OR) 3.4, 95% CI 2.7–4.3), new MI (OR 2.8, 95% CI 2.2–3.6), and the need for intra-aortic balloon pump insertion (OR 5.4, 95% CI 3.5–8.4) at 7 days and 6 months. There was no increase in use of cardiac catheterization (OR 0.8, 95% CI 0.7–1.0) or revascularization (OR 0.9, 95% CI 0.7–1.1) in patients who developed CHF. CHF is a common complication in patients presenting with non-ST segment elevation ACS and is strongly associated with adverse clinical outcomes including new MI and death. Despite this worse prognosis, patients with ACS developing CHF are less likely to be referred for invasive management.Key words: unstable angina, acute coronary syndrome, congestive heart failure, prognosis.

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Juan Carlos Kaski ◽  
Luciano Consuegra-Sanchez ◽  
Daniel J. Fernandez-Berges ◽  
Jose M Cruz-Fernandez ◽  
Xavier Garcia-Moll ◽  
...  

Objectives: We sought to assess whether plasma neopterin predicts adverse clinical outcomes in patients with NSTEACS. Background: Circulating C reactive protein (CRP), a marker of inflammation, correlates with events in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). High neopterin levels - a marker of macrophage activation - predict cardiovascular events in stable angina patients but their prognostic role in NSTEACS has not been systematically evaluated. Methods: We prospectively assessed 397 patients (74 % men) admitted with NSTEACS: 169 (42.5%) had unstable angina and 228 (57.5%) non-ST-segment elevation myocardial infarction (NSTEMI). Blood samples for neopterin and CRP assessment were obtained at admission. TIMI risk score was also assessed among other clinical and biochemical variables. The study end point was the composite of cardiac death, acute myocardial infarction and recurrent angina at 180-days. Results: Baseline neopterin concentrations (nmol/L) were similar in unstable angina and NSTEMI patients (8.3 [6.5–10.6] vs 8.0 [6.2–11.1], p = 0.54). Fifty-nine patients (14.9 %) had events during follow-up (highest third (%) 21.5 vs 1 st and 2 nd thirds 11.5, log rank 7.341, p = 0.007). On multivariable hazard Cox regression, only neopterin (highest vs 1 st and 2 nd thirds, HR 2.15, 95 % CI [1.21–3.81]) was independently associated with the combined endpoint.CRP levels, however, were not significantly different in patients with events compared to those without events (adjusted HR = 0.98, p = 0.89, 95% CI 0.80 –1.21). Conclusion: Increased neopterin levels are an independent predictor of 180-day adverse cardiac events in patients with NSTEACS.


2016 ◽  
Vol 94 (3) ◽  
pp. 205-210
Author(s):  
Zinaida D. Mikhailova ◽  
M. A. Shalenkova ◽  
P. F. Klimkin

Aim. To measure blood IL-6, IL-10, creatinine levels, calcium, sodium and potassium in blood and saliva, melatonin in urine of patients with acute coronary syndrome without ST segment elevation for the prediction of the clinical course at the posthospital stage. Material and methods. The study included 93patients with complicated (n=46) and uncomplicated (n=47) coronary syndrome without ST segment elevation. Blood IL-6, IL-10, creatinine levels, calcium, sodium and potassium in blood and saliva, melatonin in urine were determined on days 1-3 after hospitalization. 6-hydroxymelatonin was measured by HPLC in urine collected between 23 p.m. and 8 a.m., melatonin i in urine collected between 8 a.m. and 23 p.m. Results. Complicated coronary syndrome was associated with increased levels of melatonin (night), blood IL-10 and Na, salivary Na and Ca while the uncomplicated condition with increased blood melatonin (daytime), IL-6, creatinine, Ca, Na, K, and salivary K. 90 patients were followed up within 12 months after discharge. End-points developed in 36 (40%) of Original investigations them. Logistic analysis yielded variables and 2 logistic regression equations The data on night melatonin +5 and +4 were included in ROC analysis. The night melatonin +5 values over 0.7453 were associated with increased risk of complications in the post-hospital period (6 months) and values of0.7453 or lower with the enhanced probability of uncomplicated clinical course. Prognostic sensitivity was estimated at 90%, specificity at -54.39%. The night melatonin +4 values over 0.2903 were associated with increased risk of complications in the post-hospital period (12 months) and values of 0.2903 or lower with the enhanced probability of uncomplicated clinical course. Prognostic sensitivity was estimated at 77.8%, specificity at -59.26%. Conclusion. The night melatonin +5 and +4 models can be used to predict the clinical course of acute coronary syndrome during 6 and 12 months of the post-hospitalization period.


The Clinician ◽  
2020 ◽  
Vol 13 (3-4) ◽  
pp. 36-42
Author(s):  
O. V. Arsenicheva ◽  
N. N. Shchapovа

Objective: to study the risk factors for acute renal injury, the dynamics of renal function and prognosis in patients with acute coronary syndrome with ST-segment elevation (STEACS) with contrast-induced nephropathy (CIN) after primary percutaneous coronary intervention (PCI).Materials and methods. We studied 20 patients with STEACS, who developed СIN after PCI (follow-up group), and 98 patients with STEACS without СIN (comparison group). All patients were measured plasma creatinine level and glomerular filtration rate by the formula CKD-EPI before and 48 hours after PCI. CIN was detected with an increase in creatinine levels in the blood by more than 26.5 µmol / l from the baseline 48 hours after administration of radiopaque drug (RCP). Endpoints were evaluated at the hospital stage and within 12 months after PCI.Results. CIN after PCI occurred in 16.9 % of patients with STEACS. Among patients with СIN, persons aged over 75 years (60 %), with diabetes mellitus (45 %), chronic kidney disease (75 %), postinfarction cardiosclerosis (50 %), chronic heart failure of functional class III–IV (80 %), developed acute heart failure T. Killip III–IV (90 %) were significantly more often observed. The left ventricular ejection fraction was lower in patients with СIN (p <0.05). The average increase in plasma creatinine 48 hours after PCI was higher in the follow-up group (p <0.05). In patients with СIN more often, than without СIN, three-vascular lesions of the coronary bed were detected (65 and 25.5 % respectively, p <0.001). The same trend was observed, when assessing the average number of coronary artery stenoses, the number of implanted stents and the volume of RCP used. Patients with СIN, than without СIN, were longer in hospital (12.1 ± 0.96 and 10.2 ± 1.11 days respectively, p <0.05) and more often needed re-hospitalization within 12 months after PCI (34 and 4.1 % respectively, p <0.05).Summary. CIN in patients with STEACS after primary PCI was more likely to develop, if the following symptoms were present: age over 75 years, diabetes mellitus, chronic heart failure, post-infarction cardiosclerosis, chronic kidney disease, low ejection fraction of the left ventricle, initially high creatinine level, development of acute heart failure, trisovascular coronary lesion and multiple coronary stenting. The duration of hospital stay and the frequency of re-hospitalizations within a year after PCI significantly increased in patients in the CIN group.


2009 ◽  
Vol 3 (4) ◽  
pp. 153-159
Author(s):  
Marco Mascellanti

The patients presenting acute coronary syndrome without ST segment elevation can have a short and long-term risk of death or recurrent ischemic events. Therefore, the evaluation of risk is an essential step in the management of such patients. We report two cases – a 86-year-old male, and a 46-year-old one – with acute coronary syndrome with non-ST-segment elevation, showing the importance of risk assessment to determine management strategy. Two risk profile scores were used: TIMI score and GRACE score. Routine use of validated risk score may facilitate more appropriate tailoring of intensive therapies, but the clinical reasoning of the physician is essential to take right decisions.


2021 ◽  
Vol 10 (2) ◽  
pp. 60-71
Author(s):  
I. S. Trusov ◽  
A. V. Biryukov ◽  
E. M. Nifontov ◽  
R. D. Ivanchenko ◽  
E. I. Melioranskaia

Highlights. Vascular healing response after stenting depends on both, procedure- and patient-related factors. The patient's age, lipid metabolism, the presence of heart failure, myocardial infarction, and the thickness of epicardial adipose tissue affect vascular remodeling after everolimus-eluting stent implantation.Aim. To identify factors affecting vascular healing response after everolimus-eluting stent implantation in patients with non-ST segment elevation acute coronary syndrome.Methods. 45 patients with non-ST segment elevation acute coronary syndrome who underwent everolimus-eluting stent implantation were included in a study. Stenting was performed without intravascular imaging guidance. All patients underwent repeated coronary angiography and optical coherence tomography of the stented segment 6 (±2) months after the indexed procedure. 39,860 struts in 4,576 sections were analyzed. The number of uncovered and malapposed struts was estimated, and the healing score was calculated. Cardiovascular death, repeated myocardial infarction, and repeated revascularization of the stented segment 12 months after the stenting were evaluated as a combined endpoint.Results. 5 patients out of 45 reached the endpoint (11.1%), the main component of which was repeated revascularization. Patients who reached the endpoint had a lower healing score (4.5±2.6 and 19.9±17.9, respectively; p = 0.038). The healing score was lower in men (13.7±14.7 and 26.0±20.0, respectively; p = 0.041), those who had myocardial infarction at the time of stenting (5.5±6.7 for myocardial infarction and 19.8±17.9 for unstable angina, p = 0.045), and those who did not have heart failure (12.2±12.4 and 36.7±19.0, respectively; p = 0.0006). The healing score depended on the severity of the coronary lesion (24.8±19.4 for multivessel lesions, 10.0±8.7 for single-vessel lesions, and 7.3±6.3 for two-vessel lesions, respectively; p = 0.019). The linear regression reported the correlation of the healing score with age, atherogenicity coefficient, and the presence of chronic heart failure. The modified healing score depended on the epicardial fat thickness, atherogenicity coefficient, and blood urea level.Conclusion. The nature and degree of vascular remodeling after everolimus-eluting stent implantation depends on the patient's age, diagnosis, heart failure, lipid metabolism, and the severity of the coronary lesion. The evaluation of vascular healing response may influence the decision on the duration of dual antiplatelet therapy


Sign in / Sign up

Export Citation Format

Share Document